Molecular Modelling Market Research Report-Forecast till 2027

Molecular Modelling Market Research Report: by Product (Software and Services), by Application (Drug Development, Drug Discovery, and Others), by End-user (Pharmaceutical & Biotechnology Companies, Research & Academic Centers) - Forecast Till 2027

ID: MRFR/LS/2944-CR | February 2021 | Region: Global | 110 pages

Molecular Modelling Market Overview


The molecular modelling market is expected to grow at a CAGR of 15.16% from the years between 2018 and 2023. People use molecular modeling software to create 3D computer simulations of molecules in terms of structure and nature. This is invaluable because it allows them to manipulate these molecules. They can then understand how different drugs would react with humans. This is far more effective and safer than testing medicines on lab animals.  

Molecular modeling software used to be used when developing new drugs and testing them for potential side effects. However, since it’s so useful, it’s now being used in computational chemistry and materials science work and projects.  

COVID-19 Analysis of Molecular Modelling Market

COVID-19 first appeared in the world in the spring of last year. At first, this virus seemed to be nothing more than a nuisance. However, some people who got it had to be hospitalized, and a very small percentage of these people died from it. Additionally, people who recovered from it could get it again since the antibodies were short-lived. They could also suffer from long-term side effects like diabetes and partial brain damage. 

Governments realized that COVID-19 had to be contained. That’s why they imposed quarantines and lockdowns. This had some success. However, many industries were hit badly by the virus. The global molecular modelling market was no exception. The molecular modelling market is expected to gain huge growth in future. 

Many companies found it hard to get the materials and find the programmers needed to make molecular modeling software.  

Molecular Modelling Market Dynamics

Drivers

More and more scientists and researchers are using molecular modeling software to test the efficiency of drugs. They find that this is a cost-effective and safer way to bring new drugs to market faster. 

Another factor that is driving growth in the molecular modelling market is the fact that more and more people around the world are suffering from chronic long-term diseases like diabetes, Alzheimer’s, and cancer. Only effective and powerful pharma drugs can effectively treat these.

The biosimilars and biologics industries are growing fast. This has been a major factor that has driven growth in the molecular modelling market in recent years.

Opportunities

The fact that the global molecular modelling market has a high CAGR is many enticing companies in the pharma and biotech industry to invest heavily in research and development. This has led to the creation of a new generation of powerful drugs that are more effective than their predecessors and can sell at higher prices.

Restraints

It’s hard to do research and development. Also, because the research and development needed to develop these drugs are expensive, it’s hard for these companies to come up with the funding easily and quickly.

Challenges

One challenge that pharma and biotech majors will have to overcome lies in finding an effective way to raise more funds faster. 

Cumulative growth analysis

The CAGR for the global molecular modelling market is 15.16%.

Technology Analysis

Optibrium is a major British company that develops molecular modeling software. It has invested heavily in research and development to come up with a new generation of molecular modeling software programs. One of these is Stardrop. 

Stardrop is a suite of programs that uses the latest in silicon technologies to allow users to create accurate simulations of certain molecules. This allows companies to make more effective and powerful drugs and related products faster and at a lower cost.

Molecular Modelling Market Segment Overview

By Product

The global molecular modelling market produces two different types of software products:



  • Software

  • Services


By Application

There are many applications for molecular modeling software. Some of these are:



  • Drug discovery

  • Drug development

  • Others 



The drug discovery segment can be segmented further into direct drug design, indirect drug design, and molecular mimicry. The customers are research centers and agencies, academic institutions, pharma and biotech companies, and others.

By Region

There are four major regions for the global molecular modeling software market. These are;



  • The Americas

  • The European Union

  • The Asia-Pacific region

  • The Middle East and North Africa 



Molecular Modelling Market Regional Analysis

The North American region held the lion’s share of the molecular modelling market in 2015. This is expected to continue until at least 2027, given the fact that most of the major pharma and biotech companies are located either in America or in Canada.  

Many major companies have entered into strategic partnerships. This has allowed them to invest even more in research and development. The result has been amazing because this has allowed them to produce a new generation of more effective and powerful drugs. These drugs are produced according to stringent national and international standards.  

To use an example of a strategic partnership, the American Diabetes Association (ADA) has entered into a strategic partnership with Entelos Inc in terms of research. The objective is to invest even more into research and development efforts to try to come up with a new generation of more powerful and effective drugs to treat diabetes with fewer side effects. 

Instead of experimenting with these drugs on lab animals, these companies can use molecular modeling software to understand how these drugs would interact with each other and with the human body. 

The Asia-Pacific molecular modelling market is expected to have the highest CAGR of all of the regions in the world for the forecasted time period. This is largely fueled by the establishment of contract research organizations (especially in countries like India and Singapore.) Governments in the Asia-Pacific region are also becoming much wealthier. This has allowed them to spend more on healthcare. They are financing projects that use molecular modeling software much more often, and the results are amazing. The biotech and pharma companies in this region are able to produce a new generation of more powerful and effective drugs with fewer side effects. 

Another factor that is driving growth in the Asia-Pacific region is the fact that healthcare infrastructure and standards are changing for the better. 

Molecular Modelling Market Competitive Landscape

The global molecular modelling market is very competitive despite higher barriers to entry. The relatively high CAGR combined with a high return on investment (ROI) in terms of drugs introduced to the market is enticing bigger companies to enter into the market. This is especially true of pharma and biotech companies. 

As more and more companies enter the market, established players find that the only way that they can be successful is if they invest heavily in research and development. This will allow them to create and sustain a competitive advantage by allowing them to create a new generation of innovative and powerful new drugs that are more effective and have fewer side effects.

Companies are also finding that they must enter into strategic partnerships and merge with/acquire other companies to succeed with strategic partnerships. They can increase the total monetary resources they can allocate for research and development by ‘pooling the funds’ of the companies in the partnership. This allows them to produce drugs that are better, more effective, and safer in less time. 

Strategic partnerships also allow companies to strengthen their position in existing markets. It allows them to enter new markets on a strong footing. Both of these can result in much more sales revenue for the companies. 

When companies merge with or acquire each other, they can access the resources and knowledge of the companies that they have merged with or acquired. This gives them a noted competitive advantage because it allows them to create and sustain a competitive advantage by marketing innovative drugs that they may not have been able to create alone.

List of Companies



  • Cresset Acellera, Ltd.

  • Schrodinger LLC - Germany

  • Optibrium - United Kingdom

  • Biosolve-IT - Germany

  • Simulations Plus, Inc - USA

  • Chemical computing group - Canada

  • Centera, LP - 

  • OpenEye Scientific Software - USA

  • Dassault Systems - USA

  • Cambridge Crystallographic Data Centre - UK 



Recent Developments



  • Optibrium raises investment for computer-aided drug testing

  • Innovate, a British funded project, markets the next generation AI drug platform

  • Optibrium and Cheminformatics enter into a strategic partnership for MSD

  • Optibrium launches Cellera


Molecular Modelling Market Report Overview 

The global molecular modelling market is growing at a CAGR of 15%. The increasing prevalence of chronic diseases is fueling the growth. Many governments are also investing heavily in research and development. This is allowing them to support large corporate projects that are devoted to developing a new generation of more powerful and effective drugs with fewer side effects.



Report Scope:
Report Attribute/Metric Details
  Market Size   Significant Value
  CAGR   2017-2023: 15.16%
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors    Cresset Acellera, Ltd, Schrodinger LLC - Germany, Optibrium - United Kingdom, Biosolve-IT - Germany, Simulations Plus, Inc - USA, Chemical computing group - Canada, Centera, LP - , OpenEye Scientific Software - USA, Dassault Systems - USA, Cambridge Crystallographic Data Centre - UK,
  Key Market Opportunities   The Global molecular modelling market has a high CAGR is many enticing companies in the pharma and biotech industry to invest heavily in research and development.
  Key Market Drivers

  • Scientists and researchers are using molecular modeling software to test the efficiency of drugs. They find that this is a cost-effective and safer way to bring new drugs to market faster
  • The pharmaceutical and biotechnological companies would head Molecular Modelling Market


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :


    Molecular Modelling Market predicted CAGR would be 15.16% during the forecast period of 2020-2027.

    The software segment is dominating the Molecular Modelling Market.

    The drug development segment would dominate the Molecular Modelling Market with a projected valuation of USD 111.56 million.

    The pharmaceutical and biotechnological companies would head Molecular Modelling Market.

    Global Molecular Modelling Market – Summary


    The pursuit of a better life is a never-ending process and advancing technologies have seldom failed to bore fruits. Aptly supported by the latest innovations, healthcare has benefitted considerably. But a generic answer is no longer valid as the diseases are changing their features according to their real-life hosts. Hence, the need for customization arose. Growing prevalence of chronic diseases has also galvanized this need relying on which the healthcare sector is now looking for a solution in molecular modelling. Molecular modelling market is all set to become the harbinger of a new era of drug designing. To start with, a 15.46% CAGR is during the forecast period (2017-2023) in the reports of Market Research Future (MRFR) seems to be quite promising.


    Rising cases of chronic diseases have become quite daunting in their impact on the popular psyche, and it keeps the experts on their toe. Finding a solution with long-lasting upshot has become the need of the hour. Molecular modelling, many experts feel, has the potential answer. Reports published by the World Health Organization (WHO) reveals in 2015 around 8.8 million people died from cancer. To be precise, worldwide, cancers such as lung cancer, liver cancer, colorectal cancer, stomach cancer, and breast cancer caused 1.69 million, 788 thousand, 774 thousand, 754 thousand, and 571 thousand deaths, respectively. This has made the research regarding molecular modelling, even more, pertaining spurring the market growth further.


    Molecular modelling’s ability to predict the outcome of a drug composition using both computational and experimental techniques has a profound bearing on the healthcare industry. Subtle it may sound now, but in future, it can be an overarching one. Its simple methods have made it accessible in diverse fields such as computational chemistry, computational biology, and material science. It empowers researchers with a 3D view of the molecular structure which further helps in investigating, interpreting, and seeking of specific explanation regarding better drug architecture.


    However, software for such modelling is quite expensive which requires efficiency in the calculation of the potential benefit the implementer can earn upon investing. The customization of the software to suit the purpose can trigger the price to rise which can bottleneck the market.


    Opportunity:


    Countries situated near the equator have become the budding ground for many chronic diseases such as chagas, dengue, leprosy, and rabies due to problematic climactic conditions forcing these countries to employ the latest advancements into their system. Governments of developing countries have initiated education programs and projects such as the Janala Project in Bangladesh, ProjectABC in Nigeria, Tostan in Senegal, Yoza in South Africa, and BridgeIT in Tanzania, and others to create awareness regarding the conditions and healthcare IT tools.


    Segmentation:


    Based on the product, the market can be segmented by software and services. Software, by generating the maximum revenue, is helming the market and is expected to scale rapidly with an impressive CAGR of 13.55% during the forecast period. However, services can score high with the fastest CAGR during the review period, and it can rise to a stellar 18.64% to impact the market considerably. The services segment had accounted for 63.1% share of the market in 2017.


    Application-wise segmentation includes drug development, drug discovery, and others. Various prevalent diseases and growing resistance power of diseases are asking for a countermeasure owing to which drug development is witnessing the maximum expansion. A leap of about 13.26% CAGR from the current market valuation of USD 111.56 million during the forecast period is expected. Meanwhile, the drug discovery segment is expected to register the fastest CAGR of 17.30% as new methods of countering the existing diseases have turned into utmost priority.


    Based on end-users, the market consists pharmaceutical and biotechnological companies, research centers and academic institutions, and others. The evolving market requires constant researches to facilitate further trendsetting developments which have turned the pharmaceutical and biotechnological companies into market doyens. After earning USD 182.46 million in 2017, the market is eyeing for a CAGR of 13.84% during the forecast period. Research centers and academic institutions have also stepped in taking the market ahead with a promising CAGR of 19.16% projection during the forecast period.


    Regional Analysis:


    Region-wise analysis of the global market encompasses four regions namely the Americas, Europe, Asia Pacific (APAC), and the Middle East and Africa (MEA).


    Superiority in technology, advanced technology, increasing cases of chronic diseases and high healthcare investment have rightly set the ground for the Americas to becomes the market forerunners. As per the National Cancer Institute (NCI), 2014 alone had new 1,666,540 cancer cases registered. This massive patient pool contributes significantly to the growth of the market.


    Government initiatives are proving beneficial for the market in Europe. The region is second only to the Americas. According to Eurostat, Germany spend over USD 371 billion in just 2014 to have some groundbreaking progress that can shape the future healthcare industry.


    The APAC is expecting a robust growth as countries such as Singapore, Australia, Malaysia, India, and China with their huge patient pool and advancing healthcare technologies are investing substantially in research of the said market. However, lack of capital investment in various other regions can rig the market growth during the review period.


    Competition Analysis:


    Strong global presence is a definite answer for companies who are eyeing for a substantial prospect. For instance, Simulations Plus, Inc presence in all the four regions have helped it maintain a robust presence and expand portfolio which can cement its current position further.


    The market study reveals companies such as Simulations Plus, Inc, Schrödinger, LLC, Dassault Systèmes, Chemical Computing Group, OpenEye Scientific Software, BioSolve-IT, Cresset, Optibrium, Cambridge Crystallographic Data Centre, Acellera Ltd, Certara, L.P, and others as key market influencers.

    1 Report Prologue

    2 Market Introduction

    2.1 Definition 15

    2.2 Scope Of The Study 15

    2.3 List Of Assumptions 16

    2.4 Market Structure 17

    3 Research Methodology

    3.1 Research Process 19

    3.2 Primary Research 20

    3.3 Secondary Research 21

    3.4 Market Size Estimation 21

    3.5 Forecast Model 22

    4 Market Dynamics

    4.1 Introduction 24

    4.2 Drivers 24

    4.2.1 Increasing Prevalence Of Various Chronic Diseases Leading To Drug Development 24

    4.2.2 Technological Advancements In Drug Design 24

    4.2.3 Increasing Investments In Research & Development By Pharmaceutical And Biotechnology Companies 24

    4.3 Restraints 25

    4.3.1 Higher Cost Of Molecular Modelling Software 25

    4.3.2 Lack Of Skilled Healthcare IT Professionals In Low And Middle-Income Economies 25

    4.4 Opportunities 25

    4.4.1 Introduction Of Molecular Modelling Software And Services In Developing Economies 25

    5 Market Factor Analysis

    5.1 Porter’s Five Forces Model 27

    5.1.1 Threat Of New Entrants 28

    5.1.2 Bargaining Power Of Suppliers 28

    5.1.3 Bargaining Power Of Buyers 28

    5.1.4 Threat Of Substitutes 28

    5.1.5 Intensity Of Rivalry 28

    5.2 Value Chain Analysis 29

    5.2.1 Inputs 30

    5.2.2 Software Development Processes 30

    5.2.3 Output 30

    5.2.4 Marketing And Distribution 30

    5.2.5 Post-Selling Services 30

    5.3 Investment Opportunity Analysis 30

    5.4 Price Analysis 31

    6 Global Molecular Modelling Market By Product

    6.1 Introduction 33

    6.2 Software 34

    6.3 Services 35

    7 Global Molecular Modelling Market By Application

    7.1 Introduction 37

    7.2 Drug Development 38

    7.3 Drug Discovery 39

    7.4 Others 39

    8 Global Molecular Modelling Market By End User

    8.1 Introduction 41

    8.2 Pharmaceutical & Biotechnology Companies 42

    8.3 Research & Academic Centers 43

    8.4 Others 43

    9 Global Molecular Modelling Market By Region

    9.1 Introduction 45

    9.2 Americas 46

    9.2.1 North America 48

    9.2.1.1 US 50

    9.2.1.2 Canada 51

    9.2.2 South America 52

    9.3 Europe 54

    9.3.1 Western Europe 56

    9.3.1.1 Germany 58

    9.3.1.2 France 59

    9.3.1.3 U.K 60

    9.3.1.4 Italy 62

    9.3.1.5 Spain 63

    9.3.1.6 Rest Of Western Europe 64

    9.3.2 Eastern Europe 66

    9.4 Asia Pacific 68

    9.4.1 Japan 70

    9.4.2 China 71

    9.4.3 India 72

    9.4.4 Australia 74

    9.4.5 South Korea 75

    9.4.6 Rest Of Asia Pacific 76

    9.5 Middle East & Africa 78

    9.5.1 Middle East 80

    9.5.2 Africa 81

    10 Competitive Landscape

    10.1 Introduction 84

    10.2 Company Ranking 84

    11 Company Profiles

    11.1 Simulations Plus, Inc. 86

    11.1.1 Company Overview 86

    11.1.2 Financial Overview 86

    11.1.3 Products Offering 87

    11.1.4 Key Developments 87

    11.1.5 SWOT Analysis 87

    11.1.6 Key Strategy 87

    11.2 Cambridge Crystallographic Data Centre 88

    11.2.1 Company Overview 88

    11.2.2 Financial Overview 88

    11.2.3 Products Offering 88

    11.2.4 Key Developments 88

    11.2.5 SWOT Analysis 88

    11.2.6 Key Strategy 88

    11.3 Optibrium 89

    11.3.1 Company Overview 89

    11.3.2 Financial Overview 89

    11.3.3 Products Offering 89

    11.3.4 Key Developments 89

    11.3.5 SWOT Analysis 89

    11.3.6 Key Strategy 90

    11.4 Cresset 91

    11.4.1 Company Overview 91

    11.4.2 Financial Overview 91

    11.4.3 Products Offering 91

    11.4.4 Key Developments 91

    11.4.5 SWOT Analysis 92

    11.4.6 Key Strategy 92

    11.5 BioSolveIT GmbH 93

    11.5.1 Company Overview 93

    11.5.2 Financial Overview 93

    11.5.3 Products Offering 93

    11.5.4 Key Developments 93

    11.5.5 SWOT Analysis 93

    11.5.6 Key Strategy 94

    11.6 OpenEye Scientific Software 95

    11.6.1 Company Overview 95

    11.6.2 Financial Overview 95

    11.6.3 Products Offering 95

    11.6.4 Key Developments 95

    11.6.5 SWOT Analysis 96

    11.6.6 Key Strategy 96

    11.7 Chemical Computing Group 97

    11.7.1 Company Overview 97

    11.7.2 Financial Overview 97

    11.7.3 Products Offering 97

    11.7.4 Key Developments 97

    11.7.5 SWOT Analysis 97

    11.7.6 Key Strategy 98

    11.8 Acellera Ltd. 99

    11.8.1 Company Overview 99

    11.8.2 Financial Overview 99

    11.8.3 Products Offering 99

    11.8.4 Key Developments 99

    11.8.5 SWOT Analysis 99

    11.8.6 Key Strategy 100

    11.9 Dassault Systèmes 101

    11.9.1 Company Overview 101

    11.9.2 Financial Overview 101

    11.9.3 Products Offering 102

    11.9.4 Key Developments 102

    11.9.5 SWOT Analysis 102

    11.9.6 Key Strategy 102

    11.10 Schrödinger, LLC 103

    11.10.1 Company Overview 103

    11.10.2 Financial Overview 103

    11.10.3 Products Offering 103

    11.10.4 Key Developments 103

    11.10.5 SWOT Analysis 104

    11.10.6 Key Strategy 104

    11.11 Certara, L.P 105

    11.11.1 Company Overview 105

    11.11.2 Financial Overview 105

    11.11.3 Products Offering 105

    11.11.4 Key Developments 105

    11.11.5 SWOT Analysis 106

    11.11.6 Key Strategy 106

    12 Appendix

    12.1 Discussion Blue Print 108


    13 List Of Tables

    TABLE 1 LIST OF ASSUMPTIONS 16

    TABLE 2 GLOBAL MOLECULAR MODELLING MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 33

    TABLE 3 GLOBAL MOLECULAR MODELLING MARKET FOR SOFTWARE BY REGION, 2020 TO 2027 (USD MILLION) 34

    TABLE 4 GLOBAL MOLECULAR MODELLING MARKET FOR SERVICES BY REGION, 2020 TO 2027 (USD MILLION) 35

    TABLE 5 GLOBAL MOLECULAR MODELLING MARKET BY APPLICATION, 2020 TO 2027 (USD MILLION) 37

    TABLE 6 GLOBAL MOLECULAR MODELLING MARKET FOR DRUG DEVELOPMENT BY REGION, 2020 TO 2027 (USD MILLION) 38

    TABLE 7 GLOBAL MOLECULAR MODELLING MARKET FOR DRUG DISCOVERY BY REGION, 2020 TO 2027 (USD MILLION) 39

    TABLE 8 GLOBAL MOLECULAR MODELLING MARKET FOR DRUG DISCOVERY BY TYPE, 2020 TO 2027 (USD MILLION) 39

    TABLE 9 GLOBAL MOLECULAR MODELLING MARKET BY END USER, 2020 TO 2027 (USD MILLION) 41

    TABLE 10 GLOBAL MOLECULAR MODELLING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY BY REGION, 2020 TO 2027 (USD MILLION) 42

    TABLE 11 GLOBAL MOLECULAR MODELLING MARKET FOR RESEARCH & ACADEMIC CENTERS BY REGION, 2020 TO 2027 (USD MILLION) 43

    TABLE 12 GLOBAL MOLECULAR MODELLING MARKET BY REGION, 2020 TO 2027 (USD MILLION) 45

    TABLE 13 AMERICAS MOLECULAR MODELLING MARKET BY REGION, 2020 TO 2027 (USD MILLION) 46

    TABLE 14 AMERICAS MOLECULAR MODELLING MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 46

    TABLE 15 AMERICAS MOLECULAR MODELLING MARKET BY APPLICATION, 2020 TO 2027 (USD MILLION) 47

    TABLE 16 AMERICAS MOLECULAR MODELLING MARKET FOR DRUG DISCOVERY BY TYPE, 2020 TO 2027 (USD MILLION) 47

    TABLE 17 AMERICAS MOLECULAR MODELLING MARKET BY END USER, 2020 TO 2027 (USD MILLION) 47

    TABLE 18 NORTH AMERICA MOLECULAR MODELLING MARKET BY COUNTRY, 2020 TO 2027 (USD MILLION) 48

    TABLE 19 NORTH AMERICA MOLECULAR MODELLING MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 48

    TABLE 20 NORTH AMERICA MOLECULAR MODELLING MARKET BY APPLICATION, 2020 TO 2027 (USD MILLION) 49

    TABLE 21 NORTH AMERICA MOLECULAR MODELLING MARKET FOR DRUG DISCOVERY BY TYPE, 2020 TO 2027 (USD MILLION) 49

    TABLE 22 NORTH AMERICA MOLECULAR MODELLING MARKET BY END USER, 2020 TO 2027 (USD MILLION) 49

    TABLE 23 US MOLECULAR MODELLING MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 50

    TABLE 24 US MOLECULAR MODELLING MARKET BY APPLICATION, 2020 TO 2027 (USD MILLION) 50

    TABLE 25 US MOLECULAR MODELLING MARKET FOR DRUG DISCOVERY BY TYPE, 2020 TO 2027 (USD MILLION) 50

    TABLE 26 US MOLECULAR MODELLING MARKET BY END USER, 2020 TO 2027 (USD MILLION) 51

    TABLE 27 CANADA MOLECULAR MODELLING MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 51

    TABLE 28 CANADA MOLECULAR MODELLING MARKET BY APPLICATION, 2020 TO 2027 (USD MILLION) 51

    TABLE 29 CANADA MOLECULAR MODELLING MARKET FOR DRUG DISCOVERY BY TYPE, 2020 TO 2027 (USD MILLION) 52

    TABLE 30 CANADA MOLECULAR MODELLING MARKET BY END USER, 2020 TO 2027 (USD MILLION) 52

    TABLE 31 SOUTH AMERICA MOLECULAR MODELLING MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 52

    TABLE 32 SOUTH AMERICA MOLECULAR MODELLING MARKET BY APPLICATION, 2020 TO 2027 (USD MILLION) 53

    TABLE 33 SOUTH AMERICA MOLECULAR MODELLING MARKET FOR DRUG DISCOVERY BY TYPE, 2020 TO 2027 (USD MILLION) 53

    TABLE 34 SOUTH AMERICA MOLECULAR MODELLING MARKET BY END USER, 2020 TO 2027 (USD MILLION) 53

    TABLE 35 EUROPE MOLECULAR MODELLING MARKET BY REGION, 2020 TO 2027 (USD MILLION) 54

    TABLE 36 EUROPE MOLECULAR MODELLING MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 54

    TABLE 37 EUROPE MOLECULAR MODELLING MARKET BY APPLICATION, 2020 TO 2027 (USD MILLION) 55

    TABLE 38 EUROPE MOLECULAR MODELLING MARKET FOR DRUG DISCOVERY BY TYPE, 2020 TO 2027 (USD MILLION) 55

    TABLE 39 EUROPE MOLECULAR MODELLING MARKET BY END USER, 2020 TO 2027 (USD MILLION) 55

    TABLE 40 WESTERN EUROPE MOLECULAR MODELLING MARKET BY COUNTRY, 2020 TO 2027 (USD MILLION) 56

    TABLE 41 WESTERN EUROPE MOLECULAR MODELLING MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 56

    TABLE 42 WESTERN EUROPE MOLECULAR MODELLING MARKET BY APPLICATION, 2020 TO 2027 (USD MILLION) 57

    TABLE 43 WESTERN EUROPE MOLECULAR MODELLING MARKET FOR DRUG DISCOVERY BY TYPE, 2020 TO 2027 (USD MILLION) 57

    TABLE 44 WESTERN EUROPE MOLECULAR MODELLING MARKET BY END USER, 2020 TO 2027 (USD MILLION) 57

    TABLE 45 GERMANY MOLECULAR MODELLING MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 58

    TABLE 46 GERMANY MOLECULAR MODELLING MARKET BY APPLICATION, 2020 TO 2027 (USD MILLION) 58

    TABLE 47 GERMANY MOLECULAR MODELLING MARKET FOR DRUG DISCOVERY BY TYPE, 2020 TO 2027 (USD MILLION) 58

    TABLE 48 GERMANY MOLECULAR MODELLING MARKET BY END USER, 2020 TO 2027 (USD MILLION) 59

    TABLE 49 FRANCE MOLECULAR MODELLING MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 59

    TABLE 50 FRANCE MOLECULAR MODELLING MARKET BY APPLICATION, 2020 TO 2027 (USD MILLION) 59

    TABLE 51 FRANCE MOLECULAR MODELLING MARKET FOR DRUG DISCOVERY BY TYPE, 2020 TO 2027 (USD MILLION) 60

    TABLE 52 FRANCE MOLECULAR MODELLING MARKET BY END USER, 2020 TO 2027 (USD MILLION) 60

    TABLE 53 U.K MOLECULAR MODELLING MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 60

    TABLE 54 U.K MOLECULAR MODELLING MARKET BY APPLICATION, 2020 TO 2027 (USD MILLION) 61

    TABLE 55 U.K MOLECULAR MODELLING MARKET FOR DRUG DISCOVERY BY TYPE, 2020 TO 2027 (USD MILLION) 61

    TABLE 56 U.K MOLECULAR MODELLING MARKET BY END USER, 2020 TO 2027 (USD MILLION) 61

    TABLE 57 ITALY MOLECULAR MODELLING MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 62

    TABLE 58 ITALY MOLECULAR MODELLING MARKET BY APPLICATION, 2020 TO 2027 (USD MILLION) 62

    TABLE 59 ITALY MOLECULAR MODELLING MARKET FOR DRUG DISCOVERY BY TYPE, 2020 TO 2027 (USD MILLION) 62

    TABLE 60 ITALY MOLECULAR MODELLING MARKET BY END USER, 2020 TO 2027 (USD MILLION) 63

    TABLE 61 SPAIN MOLECULAR MODELLING MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 63

    TABLE 62 SPAIN MOLECULAR MODELLING MARKET BY APPLICATION, 2020 TO 2027 (USD MILLION) 63

    TABLE 63 SPAIN MOLECULAR MODELLING MARKET FOR DRUG DISCOVERY BY TYPE, 2020 TO 2027 (USD MILLION) 64

    TABLE 64 SPAIN MOLECULAR MODELLING MARKET BY END USER, 2020 TO 2027 (USD MILLION) 64

    TABLE 65 REST OF WESTERN EUROPE MOLECULAR MODELLING MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 64

    TABLE 66 REST OF WESTERN EUROPE MOLECULAR MODELLING MARKET BY APPLICATION, 2020 TO 2027 (USD MILLION) 65

    TABLE 67 REST OF WESTERN EUROPE MOLECULAR MODELLING MARKET FOR DRUG DISCOVERY BY TYPE, 2020 TO 2027 (USD MILLION) 65

    TABLE 68 REST OF WESTERN EUROPE MOLECULAR MODELLING MARKET BY END USER, 2020 TO 2027 (USD MILLION) 65

    TABLE 69 EASTERN EUROPE MOLECULAR MODELLING MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 66

    TABLE 70 EASTERN EUROPE MOLECULAR MODELLING MARKET BY APPLICATION, 2020 TO 2027 (USD MILLION) 66

    TABLE 71 EASTERN EUROPE MOLECULAR MODELLING MARKET FOR DRUG DISCOVERY BY TYPE, 2020 TO 2027 (USD MILLION) 66

    TABLE 72 EASTERN EUROPE MOLECULAR MODELLING MARKET BY END USER, 2020 TO 2027 (USD MILLION) 67

    TABLE 73 ASIA PACIFIC MOLECULAR MODELLING MARKET BY COUNTRY, 2020 TO 2027 (USD MILLION) 68

    TABLE 74 ASIA PACIFIC MOLECULAR MODELLING MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 68

    TABLE 75 ASIA PACIFIC MOLECULAR MODELLING MARKET BY APPLICATION, 2020 TO 2027 (USD MILLION) 69

    TABLE 76 ASIA PACIFIC MOLECULAR MODELLING MARKET FOR DRUG DISCOVERY BY TYPE, 2020 TO 2027 (USD MILLION) 69

    TABLE 77 ASIA PACIFIC MOLECULAR MODELLING MARKET BY END USER, 2020 TO 2027 (USD MILLION) 69

    TABLE 78 JAPAN MOLECULAR MODELLING MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 70

    TABLE 79 JAPAN MOLECULAR MODELLING MARKET BY APPLICATION, 2020 TO 2027 (USD MILLION) 70

    TABLE 80 JAPAN MOLECULAR MODELLING MARKET FOR DRUG DISCOVERY BY TYPE, 2020 TO 2027 (USD MILLION) 70

    TABLE 81 JAPAN MOLECULAR MODELLING MARKET BY END USER, 2020 TO 2027 (USD MILLION) 71

    TABLE 82 CHINA MOLECULAR MODELLING MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 71

    TABLE 83 CHINA MOLECULAR MODELLING MARKET BY APPLICATION, 2020 TO 2027 (USD MILLION) 71

    TABLE 84 CHINA MOLECULAR MODELLING MARKET FOR DRUG DISCOVERY BY TYPE, 2020 TO 2027 (USD MILLION) 72

    TABLE 85 CHINA MOLECULAR MODELLING MARKET BY END USER, 2020 TO 2027 (USD MILLION) 72

    TABLE 86 INDIA MOLECULAR MODELLING MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 72

    TABLE 87 INDIA MOLECULAR MODELLING MARKET BY APPLICATION, 2020 TO 2027 (USD MILLION) 73

    TABLE 88 INDIA MOLECULAR MODELLING MARKET FOR DRUG DISCOVERY BY TYPE, 2020 TO 2027 (USD MILLION) 73

    TABLE 89 INDIA MOLECULAR MODELLING MARKET BY END USER, 2020 TO 2027 (USD MILLION) 73

    TABLE 90 AUSTRALIA MOLECULAR MODELLING MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 74

    TABLE 91 AUSTRALIA MOLECULAR MODELLING MARKET BY APPLICATION, 2020 TO 2027 (USD MILLION) 74

    TABLE 92 AUSTRALIA MOLECULAR MODELLING MARKET FOR DRUG DISCOVERY BY TYPE, 2020 TO 2027 (USD MILLION) 74

    TABLE 93 AUSTRALIA MOLECULAR MODELLING MARKET BY END USER, 2020 TO 2027 (USD MILLION) 75

    TABLE 94 SOUTH KOREA MOLECULAR MODELLING MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 75

    TABLE 95 SOUTH KOREA MOLECULAR MODELLING MARKET BY APPLICATION, 2020 TO 2027 (USD MILLION) 75

    TABLE 96 SOUTH KOREA MOLECULAR MODELLING MARKET FOR DRUG DISCOVERY BY TYPE, 2020 TO 2027 (USD MILLION) 76

    TABLE 97 SOUTH KOREA MOLECULAR MODELLING MARKET BY END USER, 2020 TO 2027 (USD MILLION) 76

    TABLE 98 REST OF ASIA PACIFIC MOLECULAR MODELLING MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 76

    TABLE 99 REST OF ASIA PACIFIC MOLECULAR MODELLING MARKET BY APPLICATION, 2020 TO 2027 (USD MILLION) 77

    TABLE 100 REST OF ASIA PACIFIC MOLECULAR MODELLING MARKET FOR DRUG DISCOVERY BY TYPE, 2020 TO 2027 (USD MILLION) 77

    TABLE 101 REST OF ASIA PACIFIC MOLECULAR MODELLING MARKET BY END USER, 2020 TO 2027 (USD MILLION) 77

    TABLE 102 MIDDLE EAST & AFRICA MOLECULAR MODELLING MARKET BY REGION, 2020 TO 2027 (USD MILLION) 78

    TABLE 103 MIDDLE EAST & AFRICA MOLECULAR MODELLING MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 78

    TABLE 104 MIDDLE EAST & AFRICA MOLECULAR MODELLING MARKET BY APPLICATION, 2020 TO 2027 (USD MILLION) 79

    TABLE 105 MIDDLE EAST & AFRICA MOLECULAR MODELLING MARKET FOR DRUG DISCOVERY BY TYPE, 2020 TO 2027 (USD MILLION) 79

    TABLE 106 MIDDLE EAST & AFRICA MOLECULAR MODELLING MARKET BY END USER, 2020 TO 2027 (USD MILLION) 79

    TABLE 107 MIDDLE EAST MOLECULAR MODELLING MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 80

    TABLE 108 MIDDLE EAST MOLECULAR MODELLING MARKET BY APPLICATION, 2020 TO 2027 (USD MILLION) 80

    TABLE 109 MIDDLE EAST MOLECULAR MODELLING MARKET FOR DRUG DISCOVERY BY TYPE, 2020 TO 2027 (USD MILLION) 80

    TABLE 110 MIDDLE EAST MOLECULAR MODELLING MARKET BY END USER, 2020 TO 2027 (USD MILLION) 81

    TABLE 111 AFRICA MOLECULAR MODELLING MARKET BY PRODUCT, 2020 TO 2027 (USD MILLION) 81

    TABLE 112 AFRICA MOLECULAR MODELLING MARKET BY APPLICATION, 2020 TO 2027 (USD MILLION) 81

    TABLE 113 AFRICA MOLECULAR MODELLING MARKET FOR DRUG DISCOVERY BY TYPE, 2020 TO 2027 (USD MILLION) 82

    TABLE 114 AFRICA MOLECULAR MODELLING MARKET BY END USER, 2020 TO 2027 (USD MILLION) 82


    14 List Of Figures

    FIGURE 1 GLOBAL MOLECULAR MODELLING MARKET: MARKET STRUCTURE 17

    FIGURE 2 RESEARCH PROCESS OF MRFR 19

    FIGURE 3 TOP DOWN & BOTTOM-UP APPROACH 22

    FIGURE 4 PORTER'S FIVE FORCES ANALYSIS OF THE GLOBAL MOLECULAR MODELLING MARKET 27

    FIGURE 5 VALUE CHAIN: MOLECULAR MODELLING MARKET 29

    FIGURE 6 GLOBAL MOLECULAR MODELLING MARKET BY PRODUCT, 2020 & 2027 (USD MILLION) 33

    FIGURE 7 GLOBAL MOLECULAR MODELLING MARKET BY APPLICATION, 2020 & 2027 (USD MILLION) 37

    FIGURE 8 GLOBAL MOLECULAR MODELLING MARKET BY END USER, 2020 & 2027 (USD MILLION) 41

    FIGURE 9 GLOBAL MOLECULAR MODELLING MARKET BY REGION, 2020 & 2027 (USD MILLION) 45

    FIGURE 10 AMERICAS MOLECULAR MODELLING MARKET SHARE BY REGION, 2020 (%) 46

    FIGURE 11 NORTH AMERICA MOLECULAR MODELLING MARKET SHARE BY COUNTRY, 2020 (%) 48

    FIGURE 12 EUROPE MOLECULAR MODELLING MARKET SHARE BY REGION, 2020 (%) 54

    FIGURE 13 WESTERN EUROPE MOLECULAR MODELLING MARKET SHARE BY COUNTRY, 2020 (%) 56

    FIGURE 14 ASIA PACIFIC MOLECULAR MODELLING MARKET SHARE BY COUNTRY, 2020 (%) 68

    FIGURE 15 MIDDLE EAST & AFRICA MOLECULAR MODELLING MARKET SHARE BY REGION, 2020 (%) 78

    Global Molecular Modelling Market: Competitive Landscape

    Many small and large companies are engaged in the global molecular modeling market. Through extensive research, it is found that market players have adopted strategies of product launches, acquisitions, and collaborations. Based on the market study, we found some key players operating in this market which are Simulations Plus, Inc, Schrödinger, LLC, Dassault Systèmes, Chemical Computing Group, OpenEye Scientific Software, BioSolve-IT, Cresset, Optibrium, Cambridge Crystallographic Data Centre, Acellera Ltd, Certara, L.P, and others.


    Simulations Plus, Inc is one of the leading players in the market with a huge global presence and strong product range. The company has a significant presence in the Americas, Europe, Asia-Pacific, and the Middle East and Africa. Furthermore, the company is capturing emerging markets by launching new products. The company is one of the premier developers of modeling software used in drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies and provides a license to these software. Major products from the company include gastroplus, ADMET predictor, NAFLDsym, and PBPKPlus. The company is using acquisitions and collaborations as strategies to expand its business scope and penetrate the untapped markets. Moreover, the company is focusing on increasing its business area through inorganic growth strategies.


    Last year, Simulation Plus, Inc. acquired DILIsym Services, Inc. which is a leading provider of Drug-Induced Liver Injury (DILI) modeling and simulations software and contract research services. After the Agreement, DILIsym has become a wholly owned subsidiary of Simulations Plus and will continue to operate under the DILIsym name. DILIsym comprehended the revenue of over USD 3 million in 2016 and the business is expected to grow in the near future.